|
 |
| EDITORIAL |
|
| Year : 2011 | Volume
: 3
| Issue : 1 | Page : 1-3 |
|
|
J Young Pharm. 2011: What are we aiming at?
KK Mueen Ahmed
Editor-in-Chief, J Young Pharm,
| Date of Web Publication | 2-Feb-2011 |
Correspondence Address:
K K Mueen Ahmed
Editor-in-Chief, J Young Pharm
DOI: 10.4103/0975-1483.76412
How to cite this article:
Mueen Ahmed K K. J Young Pharm. 2011: What are we aiming at?. J Young Pharmacists 2011;3:1-3 |
 Quality Publication and ISI Indexing | |  |
A journal is always judged based on the quality of papers, such as original papers, reviews, editorials, letters to the editor, being published and these articles play a most crucial role in research process. A high-quality publication is a means of science communication and collaboration of scientists in their field of expertise. [1] High-quality publications attract more attention of other researchers, stimulating new ideas and becoming highly cited. They boost authors' research profile, strengthen positions of institutions supporting scientific productivity, and increase chances to get funding for future research studies. Currently, in most countries, academic promotion of an individual, recruitment, and distribution of financial sources for research are all subjected to the evaluation of a researcher/institution profile in world renowned indexing systems and catalogues, such as PubMed, Scopus, Index Copernicus, Institute for Scientific Information (ISI), etc. [2]
To achieve leading positions in academics and scientific field, academic and research institutions worldwide are now strongly encouraged to improve the quality of research studies and to publish papers in peer-reviewed journals visible in most prestigious indexing databases. [3] J Young Pharm. is now indexed with Caspur, Chemical Abstracts, DOAJ, EBSCO Publishing's Electronic Databases, Expanded Academic ASAP, Genamics JournalSeek, Global Health, Google Scholar, Health and Wellness Research Center, Health Reference Center Academic, Hinari, Index Copernicus, OpenJGate, PrimoCentral, ProQuest, PubMed, Pubmed Central, SCOLOAR, SCOPUS, SIIC databases, Summon by Serial Solutions, and Ulrich's International Periodical Directory. We are aiming at inclusion in Institution of Scientific Information (ISI) during this year. J Young Pharm. is also expecting SJR Ranking by the end of this year as we are already in SCOPUS. [Figure 1] and [Table 1] show the rate of acceptance/rejection rate for the past 2 years; we have drastically improved the refining of papers in the last year, as it can be seen, our rejection rate is higher when compared to the year 2009. Combined efforts of authors, reviewers, editorial board members, and of course, publisher will further improve the quality of papers being submitted and published. | Table 1 :Number of articles submitted along with accepted/rejected ratio during the year 2010
Click here to view |
 | Figure 1 :Acceptance and rejection rate of J Young Pharm. during the past 2 years (Courtesy: journalonweb)
Click here to view |
| Inclusion of DOI in the Cited References | | |
Many of the articles submitted to JYP have been observed for the inaccurate and incomplete references, failing to locate the source for further information about the submitted manuscript. It makes our reviewers more concerned on correctness of these references. Uniform reference locators (URLs) or digital object identifiers (DOIs) are very useful in locating references on the Web, and authors are requested to provide the link/DOI in their reference list, which will further smoothen the peer-review process. Hence, JYP submission in the year 2011 will ask for DOI (if available) or full text link for the all the references cited in the submitted manuscripts.
| Inclusion of More Reviewers | | |
On behalf of the editorial board members, I would like to thank all the reviewers who have helped us in refining the papers submitted to J Young Pharm. We acknowledge them fully for their contribution and we have published a list of all of our reviewers in page 73. We are presenting a brief report on the performance of J Young Pharm during the year 2010 [Figure 2]. Performance of our reviewers is included in [Table 2] and summary of JYP results for the year 2010 is presented in [Table 3]. We are constantly adding new reviewers; hopefully, we will have a large number of active and dedicated reviewers by this year end. Our reviewers are on time in reviewing the papers for us. Not all the time, our reviewers' response toward my invitation is fruitful. Most of our reviewers remain busy with their busy research or academic schedules. We are extremely thankful to them for spending their precious time for refining articles of J Young Pharm. | Figure 2 :Manuscript submissions to J Young Pharm. during the past 2 years (Courtesy: journalonweb)
Click here to view |
| Expansion and Restructuring of Editorial Board | | |
Members of our board take a posture of being supportive and nurturing to authors who submit papers to the journal. Instead of making our mark by citing how many papers we reject, we want to be known for helping authors become better writers and researchers. To this end, our reviewers work with the editorial leadership team as part of an editorial community which unconditionally accepts all authors who submit their papers to the journal. In turn, we ask these authors to participate wholeheartedly in the editorial process of writing and rewriting. In this approach, reviewers and editors become mentors to the authors, and as a team, we work collaboratively to produce the best papers and journal possible.
An editorial board member will be expected to perform the following responsibilities:
- review two to three new papers per quarter;
- review the revised manuscripts;
- produce supportive and useful reviews;
- participate in internal quality improvement activities (e.g., answer surveys, review new forms and procedures, provide feedback); and
- communicate with editors in a timely and professional manner.
- Benefits of the position include the following.
- Joining an exciting virtual community dedicated to improving qualitative research scholarship and scholars.
- Collaborating with an international editorial leadership team.
- Mentoring authors from around the world.
- Learning a novel and effective approach to reviewing scholarly papers.
- Receiving editorial reviewing resource materials.
- Participating in research projects to improve the editorial process.
- Learning to use new software applications for reviewing and editing.
- Improving your own scholarly writing.
- Acquiring knowledge on the latest innovations in qualitative inquiry.
- Gaining a valuable credential for tenure and promotion review.
J Young Pharm. will be expanding its editorial board during the year 2011. Active reviewers will be now included as editorial board members. Interested authors can write to us along with their brief profile for possible inclusion.
| Financial Strengthening | | |
J Young Pharm . is an official publication of InPharm Association and is being managed by self-funding. Our site ( http://www.jyoungpharm.in ) is fully dynamic, and the papers being published are now available in multiple formats such as PDF, Full text, ePUB, Sword repository plugin, eBook, etc. [4] The present global requirement of journals in different output formats is a costly process. We request all the colleges and authors to subscribe the journals and further strengthen us financially. There will be nominal pre-press charges for all the manuscripts getting published from the year 2011. This policy will remain throughout the year until next notification.
| Most Cited Papers | | |
I would like to list all the most cited papers from the year 2009. [5],[6],[7],[8],[9],[10] I encourage the authors to cite J Young Pharm. papers and utilize them in their research writings. Our citations are available in multiple formats from our website ( http://jyoungpharm.in/currentissue.asp?sabs=n ) and Citeulike page ( http://www.citeulike.org/user/jyoungpharm ) as well.
| Acknowledgments | | |
Thanks to Dr. DK Sahu and his team, Medknow Publications and Media Pvt. Ltd., Mumbai, India ( http://www.medknow.com ).
| References | | |
| 1. | Gasparyan AY, Banach M. A medium of science communication in our times. Arch Med Sci 2009;5:1-2. 
|
| 2. | Gasparyan, Armen Y. Editorial from Editorial Board Member [Thoughts on Impact Factors and Editing of Medical Journals], Infl ammation and Allergy - Drug Targets 2010;9:2-5.
|
| 3. | Vessal, K. Inclusion of the archives of Iranian medicine in Index Medicus/MEDLINE. Arch Iran Med 2006;9:304.
|
| 4. | Mueen Ahmed KK. New challenges in the new year: Phcog Mag.: 5 years of quality publication. Pharmacogn Mag 2011;7:1-2.
|
| 5. | Ahmed F, Urooj A. Glucose-lowering, hepatoprotective and hypolipidemic activities of stem bark of Ficus racemosa in streptozotocin-induced diabetic Rats [Internet]. 2009. Available from: http://www.jyoungpharm.in/text.asp? 2009/1/2/160/55749 [last cited in 2009]
|
| 6. | Shailesh T, Vipul P, Girishbhai J, Manish C. Preparation and in vitro evaluation of ethylcellulose coated egg albumin microspheres of diltiazem hydrochloride [Internet]. Available from: http://www.jyoungpharm.in/text.asp?2010/2/1/27/62209 [last cited in 2010].
|
| 7. | Phutane P, Shidhaye S, Lotlikar V, Ghule A, Sutar S, Kadam V. In vitro evaluation of novel sustained release microspheres of glipizide prepared by the emulsion solvent diffusion-evaporation method [Internet]. 2010. Available from: http://www.jyoungpharm.in/text.asp?2010/2/1/35/62210
|
| 8. | Barreto F, Sousa E, Campos A, Costa JGM, Rodrigues FFG. Antibacterial activity of Lantana camara Linn and Lantana montevidensis brig extracts from Cariri-Cearand#225; Brazil [Internet]. Available from: http://www.jyoungpharm.in/text.asp?2010/2/1/42/62211 [last cited in 2010].
|
| 9. | Sharma U, Sahu R, Roy A, Golwala D. In vivo antidiabetic and antioxidant potential of Stephania hernandifolia in streptozotocin-induced-diabetic rats [Internet]. Available from: http://www.jyoungpharm.in/text.asp?2010/2/3/255/66803 [last cited in 2010].
|
| 10. | Ilango K, Valentina P, Umarani N, Kumar T. Synthesis and characterization of 2, 5-disubstituted-1, 3, 4-oxadiazoles as potential anti-inflammatory agents [Internet]. Available from: http://www.jyoungpharm.in/text.asp?2009/1/1/72/51882 [last cited in 2009].
|
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3]
|
